• Comprehensive Solutions for Your FQHC

    According to NACHC, “community health centers serve as the primary medical home for more than 27 million people in 10,400 rural and urban communities across America.” Just one form of Federally Qualified Health Centers (FQHC), community health centers receive funds from the HRSA Health Center Program to support and serve underserved areas (HRSA). The number… Read more »

  • October 2017 – 340B Insider

    Welcome to the October edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.    340B INDUSTRY NEWS UPDATE: HOUSE ENERGY & COMMERCE OVERSIGHT SUBCOMMITTEE HEARING On October 11, the House Energy & Commerce (E&C) oversight subcommittee held a second hearing on the 340B program, focusing on how Covered… Read more »

  • Clinical Insights: August 25, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Gocovri™ (amantadine) – August 24, 2017 – Adamas Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri™ (amantadine) extended release capsules… Read more »

  • Clinical Insights: July 14, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval Blincyto® (blinatumomab) – New Expanded Indication Approval – July 11, 2017 – Amgen announced that the U.S. Food and Drug… Read more »

  • Clinical Insights: June 30, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Indication Approval No new updates.   New Drug Shortage June 21, 2017 Cromolyn Sodium Inhalation Solution, USP (Currently in Shortage) New… Read more »

  • Clinical Insights: June 2, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Rebinyn® (Coagulation Factor IX (Recombinant), GlycoPEGylated) – May 31, 2017 – Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application… Read more »

  • May 2017 – 340B Insider

    Welcome to the May edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.    CELEBRATING 25 YEARS OF THE 340B PROGRAM RxStrategies Supports Conference as Pinnacle Leader Sponsor July 10 – 12 | Washington, D.C. This year marks 25 years with the 340B program in place! Along… Read more »

  • NOVEMBER 2016 – 340B INSIDER

    Welcome to the November edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. AFFORDABLE CARE ACT – WHAT IS ON THE HORIZON RxStrategies works closely with a number of industry thought leaders to keep a pulse on issues potentially impacting the 340B Drug Pricing Program. With… Read more »

  • August 340B Insider

    Welcome to the August edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   340B RECERTIFICATION REMINDER   Recertification Deadline September 9    340B Health sent a reminder to Covered Entities (CEs) regarding the Sept. 9 deadline to recertify information in the 340B program database. It is vital to… Read more »